OBJECTIVE: To investigate and study the therapeutic effect of DRCOP regimen based on polyethylene glycol liposome doxorubicin (PLD) on patients with diffuse large B cell lymphoma (DLBCL). METHODS: A retrospective analysis was conducted on 80 patients with DLBCL admitted to our hospital from June 2016 to June 2017, and the patients were equally and randomly divided into the experimental and the control group. Patients in the experimental group were treated with the DRCOP regimen based on PLD, and the patients in the control group were treated with the traditional DRCOP regimen. The short-term clinical effects, adverse reactions, the effective rate of treatment, survival rates and cardiotoxicity of patients in the two groups were compared. The three-year survival status of the two groups was compared. RESULTS: In the experimental group, 21 cases (52.50%) of complete remission (CR) with a total effective rate of 82.50% were noticed, while 13 patients (32.50%) displayed a total effective rate of 57.50% in the control group, and the difference between the data of the two groups was statistically significant. A significant reduction of cardiotoxicity such as myocardial infarction, myocardial injury and abnormal electrocardiogram in the experimental group compared with the control group was detected (P<0.05). The most common adverse reaction was the gastrointestinal discomfort, and the experimental group exhibited lower adverse reactions rate when compared to the control group. After treatment, the improvement of the quality of life was more significant in experimental group than in the control group. Three years after operation, the difference in survival between the two groups was statistically significant (P<0.05). CONCLUSION:DRCOP regimen based on PLD has a better clinical treatment effect for patients with DLBCL, which can significantly reduce the cardiotoxicity caused by chemotherapy, with higher safety. Thus, it can effectively improve the treatment efficiency of patients and reduce the occurrence of adverse reactions. AJTR
RCT Entities:
OBJECTIVE: To investigate and study the therapeutic effect of DRCOP regimen based on polyethylene glycol liposome doxorubicin (PLD) on patients with diffuse large B cell lymphoma (DLBCL). METHODS: A retrospective analysis was conducted on 80 patients with DLBCL admitted to our hospital from June 2016 to June 2017, and the patients were equally and randomly divided into the experimental and the control group. Patients in the experimental group were treated with the DRCOP regimen based on PLD, and the patients in the control group were treated with the traditional DRCOP regimen. The short-term clinical effects, adverse reactions, the effective rate of treatment, survival rates and cardiotoxicity of patients in the two groups were compared. The three-year survival status of the two groups was compared. RESULTS: In the experimental group, 21 cases (52.50%) of complete remission (CR) with a total effective rate of 82.50% were noticed, while 13 patients (32.50%) displayed a total effective rate of 57.50% in the control group, and the difference between the data of the two groups was statistically significant. A significant reduction of cardiotoxicity such as myocardial infarction, myocardial injury and abnormal electrocardiogram in the experimental group compared with the control group was detected (P<0.05). The most common adverse reaction was the gastrointestinal discomfort, and the experimental group exhibited lower adverse reactions rate when compared to the control group. After treatment, the improvement of the quality of life was more significant in experimental group than in the control group. Three years after operation, the difference in survival between the two groups was statistically significant (P<0.05). CONCLUSION:DRCOP regimen based on PLD has a better clinical treatment effect for patients with DLBCL, which can significantly reduce the cardiotoxicity caused by chemotherapy, with higher safety. Thus, it can effectively improve the treatment efficiency of patients and reduce the occurrence of adverse reactions. AJTR
Authors: Natalia M Salwowska; Katarzyna A Bebenek; Dominika A Żądło; Dominika L Wcisło-Dziadecka Journal: J Cosmet Dermatol Date: 2016-06-21 Impact factor: 2.696